Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo?

INVESTIGATING

While R55 partially rescues retromer association in vitro, its therapeutic potential in animal models or clinical settings remains unknown. This translational gap is critical for determining whether retromer stabilization represents a viable treatment strategy for Parkinson's disease. Gap type: open_question Source paper: Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation. (2016, The Journal of biological chemistry, PMID:27385586)

Priority: 0.87 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo? is a 0.87 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: investigating.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
1
Debates
1.00
Avg Quality
30%
Resolution
0
Mechanistic Families
Gap Resolution Progress30%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

enhances (1)

R55APP retrieval from endosomes to trans-Golgi network

improves (1)

R55lysosomal function

restores (1)

R55VPS35-WASH complex assembly

stabilizes (1)

R55retromer complex
🕑 Activity Feed
🎭 Can retromer-stabilizing compounds like R55 prevent neurodeg q=1.00 2026-04-26T16:10
update on knowledge_gap by None 2026-04-22T14:14
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps